Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation

NCT07318649 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
120
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Suzhou Genhouse Bio Co., Ltd.